2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Phase 2 Active not recruiting 50 enrolled University of Arkansas Janssen, LP · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects

Timeline

Start: 2017-07-01
Primary completion: 2027-10
Completion: 2028-10

Publications

Pawlyn C. High-risk myeloma: a challenge to define and to determine the optimal treatment. Lancet Haematol. 2021 Jan;8(1):e4-e6. doi: 10.1016/S2352-3026(20)30361-6. Epub 2020 Dec 22. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Daratumumab	Monoclonal antibody	—	Intravenous
Background	Bortezomib	Small molecule	—	Intravenous
Background	Carfilzomib	Other / unclassified	—	Intravenous
Background	Cisplatin	Other / unclassified	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	—	Intravenous
Background	Dexamethasone	Small molecule	—	Oral
Background	Doxorubicin	Other / unclassified	—	Intravenous
Background	Etoposide	Small molecule	—	Intravenous
Background	Lenalidomide	Other / unclassified	—	Oral
Background	Melphalan	Small molecule	—	Intravenous
Background	Thalidomide	Other / unclassified	—	Oral

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Summary

Timeline

Publications

Drugs

Indications